于2023年以按收益计量的市场份额计，九源生物若干产品在各自的产品头别中属于首款获批商业化国产产品并维持竞争地位。当中最瞩目的是其药械组合产品骨优导，根据灼识咨询的资料，其为中国首款获准销售的含rhBMP-2骨修复材料，于2023年中国骨修复材料市场中按销售收益计排名第一。Jiuyuan Gene (02566) was first listed. According to the announcement, the price per share was HK$12.42. A total of 45.3988 million shares were issued, with a total of 200 shares per lot, with a net proceeds of approximately HK$0.485 billion. As of press release, it decreased by 39.61% to HK$7.5, with a turnover of HK$83.8925 million.
The Zhitong Finance App learned that Jiuyuan Gene (02566) was first listed. According to the announcement, the price was HK$12.42 per share. A total of 45.3988 million shares were issued, 200 shares per lot, with a net proceeds of about HK$0.485 billion. As of press release, it decreased by 39.61% to HK$7.5, with a turnover of HK$83.8925 million.
According to the prospectus, Jiuyuan Gene was founded in 1993. It is a Chinese biopharmaceutical company headquartered in Zhejiang Province. It has more than 30 years of experience in R&D, production and commercialization of biopharmaceuticals and medical devices. The company focuses on four rapidly growing treatment areas: orthopedics, metabolic diseases, oncology and hematology. Notably, the company is not in the business of genetic engineering.
In 2023, in terms of market share measured by revenue, several products of Jiuyuan Biotech were the first domestically produced products approved for commercialization in their respective product categories and maintained a competitive position. Among them, the most notable one is its pharmaceutical combination product bone optimization. According to Insight Consulting, it is the first bone repair material containing rhBMP-2 approved for sale in China, ranking first in terms of sales revenue in the 2023 Chinese bone repair materials market.
